Table 3.

Post-primary and post-booster serotype specific immunoglobulin G concentrations of 0·35 μg/mL or higher

	Post-primary group 1 (2 m, 4 m; Nmax=97)	Post-primary group 2 (3 m; Nmax=102)	p value*	Post-boost group 1 (2 m, 4 m, 12 m; Nmax=91)	Post-boost group 2 (3 m, 12 m; Nmax=86)	p value*
1	95·9% (89·8–98·9); (93/97)	74·0% (64·3–82·3); (74/100)	<0·0001	100%; (96·0–100); (91/91)	100% (95·8–100); (86/86)	n/a
3	34·5% (24·5–45·7); (29/84)	39·5% (29·2–50·7); (34/86)	0·53	75·9%; (65·5–84·4); (66/87)	78·8% (68·6–86·9); (67/85)	0·72
4	92·8% (85·7–97); (90/97)	64·4% (54·2–73·6); (65/101)	<0·0001	98·9%; (94·0–100); (90/91)	100% (95·8–100); (86/86)	1·00
5	89·6% (81·7–94·9); (86/96)	39·2% (29·7–49·4); (40/102)	<0·0001	98·9%; (94·0–100); (90/91)	100% (95·8–100); (86/86)	1·00
6A	84·4% (75·5–91); (81/96)	12·9% (7–21);(13/101)	<0·0001	100%; (96·0–100); (90/90)	100% (95·8–100); (86/86)	n/a
6B	34·0% (24·7–44·3); (33/97)	1·0% (0–5·3);(1/102)	<0·0001	100%; (96·0–100); (90/90)	97·7% (91·9–99·7); (84/86)	0·24
7F	97·9% (92·7–99·7); (95/97)	86·1%; (77·8–92·2); (87/101)	0·003	100%; (96·0–100); (91/91)	100% (95·8–100); (86/86)	n/a
9V	79·4% (70–86·9); (77/97)	16·8%; (10·1–25·6); (17/101)	<0·0001	100%; (96·0–100); (91/91)	100% (95·8–100); (86/86)	n/a
14	94·8% (88·4–98·3); (92/97)	86·3% (78–92·3); (88/102)	0·053	100%; (96·0–100); (91/91)	100% (95·8–100); (86/86)	n/a
18C	81·4% (72·3–88·6); (79/97)	33·7% (24·6–43·8); (34/101)	<0·0001	100%; (96·0–100); (91/91)	100% (95·8–100); (86/86)	n/a
19A	91·8% (84·4–96·4); (89/97)	44·1% (34·3–54·3); (45/102)	<0·0001	100%; (96·0–100); (91/91)	100% (95·8–100); (86/86)	n/a
19F	100% (96·3–100); (97/97)	79·2% (70–86·6); (80/101)	<0·0001	100%; (96·0–100); (91/91)	100% (95·8–100); (86/86)	n/a
23F	57·7% (47·3–67·7); (56/97)	5·9% (2·2–12·4); (6/102)	<0·0001	100%; (96·0–100); (91/91)	95·3% (88·5–98·7); (82/86)	0·054

Data are % (95% CI) [n/N] unless otherwise states. m=month.

^*Fisher's exact test.